Ceftriaxone
NDC Package 0703-0359-01
Package Information
Ceftriaxone is used to treat a wide variety of bacterial infections. Marketed by Teva Parenteral Medicines, Inc., this product is identified by NDC 0703-0359 and is authorized under FDA application ANDA065274.
Identification & Billing
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 0703 - Teva Parenteral Medicines, Inc.
- 0703-0359 - Ceftriaxone
- 0703-0359-01 - 1 VIAL, PHARMACY BULK PACKAGE in 1 BOX / 100 mL in 1 VIAL, PHARMACY BULK PACKAGE
- 0703-0359 - Ceftriaxone
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 0703-0359-01 identifies a specific commercial package of 1 vial, pharmacy bulk package in 1 box / 100 ml in 1 vial, pharmacy bulk package of Ceftriaxone, labeled by Teva Parenteral Medicines, Inc.. This product is billed for "EA" each discreet unit and contains an estimated amount of 1 billable units per package. This is formulated for use and contains as the active substance.
Is this product currently listed with the FDA?
This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Teva Parenteral Medicines, Inc. on December 21, 2007. The current certification is valid through January 31, 2013.
What are the primary indications for this medication?
Ceftriaxone is used to treat a wide variety of bacterial infections. This medication belongs to a class of drugs known as cephalosporin antibiotics. It works by stopping the growth of bacteria. This drug is not recommended for use in newborns with high blood bilirubin levels and premature infants due to increased risk of side effects. Ask the doctor or pharmacist for details.
How is this Teva Parenteral Medicines, Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 00703035901. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 1 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.